Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects

NCT ID: NCT02905682

Last Updated: 2019-09-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 190 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-09-30
• Study Completion Date: 2017-09-27

Brief Summary

The purpose of this trial is to demonstrate efficacy of desmopressin ODT against placebo for the treatment of female subjects with nocturia due to nocturnal polyuria, during 12 weeks of treatment.

Conditions

Nocturia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Desmopressin

Desmopressin ODT

Group Type: EXPERIMENTAL

Desmopressin

Intervention Type: DRUG

Placebo

Placebo ODT

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

Desmopressin

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Other Intervention Names

FE 992026

Eligibility Criteria

Inclusion Criteria

• Written informed consent prior to performance of any trial-related activity
• Woman ≥20 years of age
• Nocturia symptoms present for ≥6 months prior to trial entry at Visit 1
• ≥2 nocturnal voids at the end of screening period prior to Visit 2
• Nocturnal polyuria at the end of screening period prior to Visit 2
• Bothered by nocturia on the Hsu 5-point Likert bother scale at Visit 1 and Visit 2
• Has given agreement about contraception during the trial

Exclusion Criteria

• Evidence of any significant voiding dysfunction resulting in abnormally low bladder capacity at the end of the screening period prior to Visit 2
• History or evidence of significant obstructive sleep apnoea
• History or diagnosis of any of the following urological diseases at Visit 1:

• Interstitial cystitis or bladder pain disorder
• Stress urinary incontinence or mixed incontinence, where stress incontinence is the predominant component based on prior history
• Chronic pelvic pain syndrome
• Surgical treatment, including transurethral resection, for bladder outlet obstruction (BOO) within the past 6 months prior to Visit 1
• Symptoms of severe over-active bladder (OAB):

• Defined as an over-active bladder symptom score (OABSS) ≥12 at Visit 1
• Defined as a mean of >8 voids and a mean of ≥1 urgency episode per 24 hours at the end of the screening period prior to Visit 2
• Genito-urinary tract pathology that can in the investigator's opinion be responsible for urgency or urinary incontinence at Visit 1
• Complication of cancer or a history of cancer which has not been in remission for the last 5 years at Visit 1
• Current or a history of urologic malignancies, any lower urinary tract surgery, previous pelvic irradiation, or neoplasia at Visit 1
• History of any neurological disease affecting bladder function or muscle strength at Visit 1
• Urinary retention or a post void residual volume >150 mL
• Habitual or psychogenic polydipsia based on medical history at Visit 1 or 24 hour urine output of >2.8 L based on the voiding diary at Visit 2
• Central or nephrogenic diabetes insipidus at Visit 1
• Syndrome of inappropriate antidiuretic hormone secretion at Visit 1
• Suspicion or evidence of cardiac failure at Visit 1
• Uncontrolled hypertension at Visit 1
• Uncontrolled diabetes mellitus at Visit 1
• Hyponatraemia (serum sodium level <135 mmol/L) at Visit 1
• Renal insufficiency at Visit 1
• Hepatic and/or biliary diseases at Visit 1
• Known or suspected hypersensitivity to desmopressin ODTs or previous desmopressin treatment for nocturia at Visit 1
• Pregnancy, breastfeeding, or a plan to become pregnant during the period of the clinical trial.
• Known alcohol or substance abuse at Visit 1
• Work or lifestyle that may interfere with regular night-time sleep at Visit 1, e.g., shift workers
• Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, or language barrier that, in the judgment of the investigator, would impair participation in the trial at Visit 1
• Use of any prohibited therapy during the trial period

• Minimum Eligible Age: 20 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Ferring Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Global Clinical Compliance

Role: STUDY_DIRECTOR

Ferring Pharmaceuticals

Locations

Investigational site (there may be other sites in this country)

Tokyo, , Japan

Countries

Japan

References

Yamaguchi O, Juul KV, Falahati A, Yoshimura T, Imura F, Kitamura M. Efficacy and safety of 25 and 50 mug desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program. Low Urin Tract Symptoms. 2020 Jan;12(1):8-19. doi: 10.1111/luts.12276. Epub 2019 Aug 9.

Reference Type: RESULT

PMID: 31397969 (View on PubMed)

Other Identifiers

000129

Identifier Type: -

Identifier Source: org_study_id